<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:230820577;
mso-list-template-ids:582261250;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:352920572;
mso-list-template-ids:1786702492;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:587348953;
mso-list-template-ids:-1914529626;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1528786545;
mso-list-template-ids:1438962884;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:2018342759;
mso-list-template-ids:-562007340;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5
{mso-list-id:2131121426;
mso-list-type:hybrid;
mso-list-template-ids:-1227969052 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://themarkfoundation.org/emerging-leader-award/" target="_blank">Mark Foundation for Cancer: Emerging Leader Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact,
high-risk projects that are distinct from their current research portfolio. The grant amount is $250,000 per year for three (3) years totaling $750,000. Indirect costs are not to exceed 10% of direct costs and are included in total.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Eligibility particularities include:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Applicants must be three to nine years from the start of an independent faculty research appointment as of December 31, 2021 (i.e., the official start date of the appointment
must fall within the calendar years 2012-2018).<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">This award is not intended to be the main source of funding for the applicant’s laboratory. Applicants must therefore demonstrate multi-year independent funding that sustains
the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review stage.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due May 3, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: April 20.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.lungcancerresearchfoundation.org/wp-content/uploads/RFP-2021-Research-Grant-on-Disparities-in-Lung-Cancer.pdf" target="_blank">Lung Cancer Research Foundation: Disparities in Lung
Cancer</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">While scientific advances steadily continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic
status populations and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound
these disparities. We encourage applications on a wide variety of disparities-related topics including but not limited to the following:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Gender disparities in lung cancer burden<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Causes and risk factors for lung cancer among never smokers<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Genetic and gene-environment interactions<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Contribution of healthcare access and quality to disparities in outcomes<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-family:Palatino">Disparities related to other factors such as geography, socioeconomic status, and age<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 7, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: April 26.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.gerberfoundation.org/how-to-apply/" target="_blank">Gerber Foundation: Pediatric Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Gerber Foundation is dedicated to enhancing the quality of life of infants and young children, with an emphasis on children under three years of age. The foundation is accepting applications for research
projects aimed at identifying solutions to common everyday issues and problems in the field of children’s health and nutrition. Of particular interest to the foundation are projects offering substantial promise of meaningful advances in prevention and treatment
of disease and those with broad and general applicability.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Research program focus areas identified by the foundation include:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo9"><span style="font-family:Palatino">Pediatric Health — Projects that promote health and prevent or treat disease. Of particular interest to the foundation are applied research projects
focused on reducing the incidence of neonatal and early childhood illnesses, or those improving cognitive, social, and emotional aspects of development.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo9"><span style="font-family:Palatino">Pediatric Nutrition — Projects that assure adequate nutrition to infants and young children, including applied research that evaluates the provision
of specific nutrients and their related outcomes.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l5 level1 lfo9"><span style="font-family:Palatino">Environmental Hazards (Nutrient Competitors) — Projects that document the impact of, or ameliorate the effects of, environmental hazards on the growth
and development of infants and young children.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Major target areas for research include new diagnostic tools that may be more rapid, more specific, more sensitive, or less invasive; treatment regimens that are novel, less stressful or painful, more
targeted, have fewer side effects, and/or provide optimal dosing; symptom relief; preventative measures; assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and risk assessment tools or measures for environmental hazards, trauma, etc.
The foundation is interested in supporting projects that will result in “new” information, treatments, or tools that result in a change in practice; it rarely funds projects that are focused on sharing current information with parents or caregivers. Grants
of up to $350,000 over up to three years will be awarded. Novice researchers follow the same process as regular grants, are limited to no more than $20,000 in total funding, and need to apply under the guidance of a mentor.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Concept paper due May 15, 2021 and November 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for May 15 due date: May 3.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://chanzuckerberg.com/rfa/ancestry-networks-human-cell-atlas/">Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">To cure, prevent, or manage all diseases, scientific research should include people of all ancestries. To help advance that vision, the
<a href="https://chanzuckerberg.com/">Chan Zuckerberg Initiative</a> (CZI) has launched a <a href="https://chanzuckerberg.com/rfa/ancestry-networks-human-cell-atlas">new funding opportunity</a> aimed at expanding the ancestral diversity of the samples in the <a href="https://www.humancellatlas.org/" target="_blank">Human
Cell Atlas</a> (HCA), an international effort to map all cells in the human body as a foundational resource for understanding health and disease.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Diseases manifest differently in different people, and ancestry is one factor that impacts disease severity, outcome, and treatment. Individuals of European ancestry account for <a href="https://www.vox.com/science-and-health/2018/10/22/17983568/dna-tests-precision-medicine-genetics-gwas-diversity-all-of-us" target="_blank">80
percent</a> of genomics data, and studies based on a narrow slice of ancestral background are often not generalizable to all people. To help fill these gaps in scientific knowledge, the Ancestry Networks for the Human Cell Atlas Request for Applications (RFA)
will support teams of researchers to generate healthy, single-cell reference data from historically understudied populations.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Ancestry Networks RFA builds off of CZI’s experience supporting the work of ten collaborative research teams that
<a href="https://cziscience.medium.com/incentivizing-more-representative-research-2d610b7c19e8" target="_blank">
studied tissue samples from a diversity of populations</a>, including people who are Black, Latinx, Asian, and Indigenous, as an initial step in addressing equal representation in the HCA. The new RFA will support collaborative networks of researchers for three-year
projects. Teams should consist of at least three and up to ten principal investigators, including at least one computational biologist or data scientist and one expert in single-cell biology. Community-based participatory researchers should be involved in
the collaboration to ensure that the research is attuned to the needs of and connected with the participating donor communities.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Ancestry Networks will collectively generate new tools, open source analysis methods, and openly available data from underrepresented donors across multiple tissue types and will provide valuable contributions
to the HCA community. Example projects could include the generation of data from organs and tissues from a single or multiple ancestral groups; the development and sharing of tissue resources that will support standards, protocols, and tissue access to researchers;
and the expansion of community engagement or donor recruitment programs and models.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 25, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: May 12.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-021.html?utm_medium=email&utm_source=govdelivery">Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical
Trial Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose
unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary
data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and inequities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 28, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: May 17.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://tealwalk.org/beneficiaries/" target="_blank">Louisa M. McGregor Ovarian Cancer Foundation (T.E.A.L.): Medical Research and Awareness Program Beneficiary</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Tell Every Amazing Lady® About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation 2021 Medical Research Program offers funding in support of ovarian cancer research studies that
are most aligned with their mission as determined by the T.E.A.L.® board of directors and scientific advisory board. The mission of T.E.A.L.® is to promote public awareness of and education about the signs, symptoms, and risk factors of ovarian cancer, provide
support to survivors, and raise funds for research in order to find a cure. Budget: $15,000 per year; no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due May 31, 2021.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 17.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-183.html">Developing Digital Therapeutics for Substance Use Disorders (UG3 / UH3 Clinical Trial optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented
opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients
with SUD.The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical
development and testing of new DTx or existing DTx developed for other indications.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 4, 2021; December 6, 2021; August 4, 2022; December 6, 2022; August 4, 2023; December 6, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for August 4, 2021 due date: July 22.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.google.com/url?q=https://www.nsf.gov/funding/pgm_summ.jsp?pims_id%3D5316%26WT.mc_id%3DUSNSF_39%26WT.mc_ev%3Dclick&sa=D&source=calendar&usd=2&usg=AOvVaw2SRSvQ8T1PgCajqDL3tsED" target="_blank">NSF:
Cognitive Neuroscience</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by
the program include attention, learning, memory, decision-making, language, social cognition, and emotions. Proposals with animal models are appropriate only if they include a comparative element with human subjects. Proposals focused on behavioral, clinical
or molecular mechanisms will not be considered for this program. Additionally, proposals directed at understanding low-level sensorimotor processes or restricted to model-based simulations of neural data will not be considered, unless they are embedded in
a cognitive question related to one of the central research topics listed above. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">August 13, 2021; February11, 2022; and August 13, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for August 13, 2021 due date: August 2.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-21-004.html">Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01
Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research
that addresses SRD in order to improve minority health or reduce health disparities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 24, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: August 11.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.nsf.gov/pubs/2019/nsf19547/nsf19547.htm" target="_blank">NSF / NIH: Science of Science Policy Approach to Analyzing and Innovating the Biomedical Research Enterprise (SCISIPBIO)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">SCISIPBIO supports research that advances the scientific basis of science and innovation policy, with a focus on the biomedical sciences. Consistent with the SciSIP program, SCISIPBIO will fund the development
of models, analytical tools, data and metrics that can inform science policy and the development of the scientific enterprise. SCISIPBIO welcomes individual and collaborative research projects and places a high priority on interdisciplinary research and on
broadening participation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due September 9, 2021 and February 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for September 9 due date: August 26 (due to Labor Day holiday).</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-015.html" target="_blank">NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The <a href="https://commonfund.nih.gov/pioneer" target="_blank">
NIH Director’s Pioneer Award Program</a> supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the
program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic
locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied,
and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s
research program or elsewhere. The NIH Director’s Pioneer Award is a component of the
<a href="http://commonfund.nih.gov/highrisk/" target="_blank">High-Risk, High-Reward Research (HRHR) Program</a> of the
<a href="http://commonfund.nih.gov/" target="_blank">NIH Common Fund</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due September 10, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: August 30.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-010.html">Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer’s Disease and Related Dementias (R25 –
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The objective of this FOA is to support short-term intensive courses or summer institutes for skills development on one of the three topics below; these have been identified by the National Institute on
Aging as high priority needs in order to advance behavioral and social sciences research on AD/ADRD. This FOA particularly encourages development of courses that have a broad reach (i.e., beyond the applicant institution, and/or can be widely disseminated),
as the goal of this FOA is to make the educational courses available to a wide range of investigators. Consideration should be given to course design that allows for virtual participation of both students and faculty, and plans for archiving and making publicly
available didactic content including course curricula and videotaped lectures. In addition, courses should be designed to help recruit new and diverse research investigators into aging research and to provide participants with both formal and informal opportunities
to interact with one another and with course faculty (in order to provide individual attention and to facilitate the formation of research collaborations). Finally, responsive applications will incorporate material on how the particular methodology or topic
of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in AD/ADRD or how they can be reduced.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 4, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: September 21.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-009.html">Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 – Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to support short courses geared towards advancing selected priority topic areas identified by the National Institute on Aging (NIA) in order to
advance research in the behavioral and social sciences. This FOA targets the following three priority research areas: 1) genomics for social scientists; 2) interdisciplinary social science research in aging; and 3) reproducibility in the social and behavioral
sciences. Responsive applications will incorporate material on how the particular methodology or topic of focus can be employed to improve scientific understanding of the mechanisms underlying disparities in the aging process/aging outcomes or how such disparities
can be reduced. Additional goals of the FOA are to help recruit new and diverse research investigators into aging research and to provide course participants with formal and informal opportunities to interact with one another and with course faculty (in order
to provide individual attention and to facilitate the formation of research collaborations).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 4, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: September 21.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-004.html" target="_blank">Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed); Center for
Tobacco Products</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) – Center for
Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study,
the National Health and Nutrition Examination Survey, the National Heart, Lung and Blood Institute’s Biologic Specimen and Data Repository Information Coordinating Center, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Proposed research
should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses
to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH
using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA’s regulation
of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the FDA-CTP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">October 8, 2021; August 8, 2022; and March 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 8 due date: September 27.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-003.html" target="_blank">Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional
and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug
Administration (FDA) – Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally
representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets
that may inform tobacco regulatory actions in the US. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results
from this FOA are expected to generate findings and data that are directly relevant in informing the FDA’s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research
priorities related to the regulatory authority of the FDA-CTP.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 8, 2021; August 8, 2022; and March 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for October 8 due date: September 27.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-135.html">BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding
of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative
data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so
that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and
should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due October 15, 2021; June 10, 2022; October 14, 2022; June 9, 2023; October 13, 2023; and June 7, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 15, 2021 due date: October 4.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-190.html" target="_blank">Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel
scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for November 8, 2021 due date: October 26.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b></span><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>